A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers. A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers

Gene sets enriched in tumor tissue in response to dosing with ivuxolimab from eight paired biopsies of patients dosed with ≥ 1.5 mg/kg indicated that gene sets associated with immune activation and inflammation were among those most enriched (higher positive normalized enrichment score [NES]) with the lowest adjusted P values. Overall design: Whole transcriptome sequencing of paired (pre/post-dose) tumor samples from patients treated with ≥ 1.5 mg/kg of ivuxolimab. Whole transcriptome sequencing was performed by Personalis using ACE ImmunoID assay.